What is tirzepatide?
Tirzepatide is a once-weekly injectable medication that activates GIP and GLP-1 receptors. It affects blood glucose, appetite, food intake, and gastric emptying. Mounjaro and Zepbound contain tirzepatide, but the brand-specific FDA indication and prescribing information matter.
What is it FDA-approved for?
Mounjaro is labeled as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Zepbound is labeled for chronic weight management together with a reduced-calorie diet and increased physical activity in adults with obesity, or overweight plus at least one weight-related condition. The current Zepbound label also contains additional specific indications. Eligibility on paper does not replace an individualized benefit-risk evaluation.
Brand names are not interchangeable statements of indication. Always use the current FDA label for the specific product and purpose being discussed.
How much benefit did trials show?
In the SURPASS program, adults with type 2 diabetes had clinically relevant reductions in A1C and body weight. In SURMOUNT-1, adults with obesity or overweight plus a weight-related condition lost an average of roughly 15% to 21% of baseline weight at 72 weeks across the studied tirzepatide doses, compared with about 3% with placebo. These are trial averages, not individual predictions.
Results depend on the population, dose tolerated, duration, adherence, nutrition, activity, and other treatment. An advertising comparison is not a substitute for reading the full study.
What are the most common adverse effects?
Nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal discomfort are common, particularly during dose escalation. Severe symptoms can lead to dehydration, acute kidney injury, or discontinuation. The risk of hypoglycemia rises when tirzepatide is used with insulin or an insulin secretagogue such as a sulfonylurea.
Gallbladder disease and biliary events deserve attention. Acute pancreatitis has been reported; severe persistent abdominal pain, especially when it radiates to the back or occurs with vomiting, requires prompt evaluation.
Contraindications and important precautions
Current U.S. labels contraindicate tirzepatide in people with a personal or family history of medullary thyroid carcinoma, in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and after a known serious hypersensitivity reaction to tirzepatide or an excipient. Thyroid C-cell tumors occurred in rats; whether tirzepatide causes these tumors in humans is unknown.
Pregnancy or plans for pregnancy, breastfeeding, severe gastrointestinal disease or gastroparesis, previous pancreatitis, gallbladder disease, diabetic retinopathy, kidney problems related to dehydration, and concurrent medications require individualized review. Before surgery or deep sedation, the procedural and anesthesia teams should know that the medication can delay gastric emptying.
What about lean mass?
As with other substantial weight loss, some weight reduction is lean mass. In a DXA substudy of SURMOUNT-1, about three quarters of the weight lost was fat mass and one quarter was lean mass. Lean mass is not identical to skeletal muscle, but the finding supports attention to adequate nutrition, resistance exercise, function, sleep, and follow-up—especially for older or frail adults and people with kidney disease.
Can weight return after stopping?
Yes. In SURMOUNT-4, participants switched from tirzepatide to placebo after initial weight loss regained a substantial amount of weight, while continued treatment maintained and extended the reduction. Obesity is a chronic condition, so a plan built only around “a few months” of medication may not address long-term maintenance.
Compounded, counterfeit, or unapproved products
FDA requirements for compounded drugs are specific and have changed as supply conditions have changed. Unapproved products do not undergo the same FDA review for safety, effectiveness, and quality. Incorrect ingredients, concentration, sterility, storage, and labeling can create serious risk. Products sold online as “research use only” or without a legitimate prescription should not be assumed safe.
Frequently asked questions
Does tirzepatide cause thyroid cancer?
Thyroid C-cell tumors occurred in rats. It is not known whether tirzepatide causes medullary thyroid carcinoma in humans. The FDA boxed warning and contraindications must be taken seriously.
Is Mounjaro FDA-approved for weight loss?
Mounjaro’s U.S. label is for type 2 diabetes. Zepbound is the tirzepatide product with the FDA weight-management indication. A clinician and pharmacist should use the correct product label and indication.
Can tirzepatide cause low blood sugar?
The risk is usually lower when tirzepatide is used alone. It rises when combined with insulin or sulfonylureas and may require clinician-directed medication adjustment.
Will I need it forever?
There is no universal answer. The decision depends on benefit, tolerability, risk, cost, access, preferences, and the maintenance plan. Many trial participants regained weight after withdrawal.
What should I do before surgery?
Tell the surgeon, proceduralist, and anesthesia team. Decisions about holding the medication depend on the procedure, symptoms, dose-escalation phase, and the current perioperative protocol.
What is the best dose?
The appropriate dose follows the product label and an individual clinical assessment. This article does not provide starting, escalation, or personal dosing instructions.
Brief explanations are also published on Instagram. This article is the fuller, referenced version.
Follow @dreliastamerKey references
- FDA. Mounjaro (tirzepatide) Prescribing Information, 2026.
- FDA. Zepbound (tirzepatide) Prescribing Information, 2026.
- FDA. Policies and safety considerations for compounded GLP-1 products, 2026.
- Jastreboff AM et al. Tirzepatide once weekly for obesity (SURMOUNT-1). NEJM, 2022.
- Frías JP et al. Tirzepatide versus semaglutide in type 2 diabetes (SURPASS-2). NEJM, 2021.
- Aronne LJ et al. Tirzepatide withdrawal and maintenance (SURMOUNT-4). JAMA, 2024.
- Look M et al. Body composition changes with tirzepatide. Diabetes, Obesity and Metabolism, 2025.
Compare strong, moderate, weak, and insufficient evidence about tirzepatide claims.
Open the evidence summary